“eisai” Archives

in
Entry Author Date Location
Biogen’s AdComm Meeting Will Test FDA’s “Substantial Evidence” Flexibility 10/08/20 Boston
Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug 07/29/20 Europe
Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More 07/24/20 National
Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing 07/08/20 Boston
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More 02/14/20 National
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks 02/13/20 National
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More 01/03/20 National
Dova Pharmaceuticals Agrees to Sobi Acquisition, Shares Jump 38% 09/30/19 Raleigh Durham
Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More 09/20/19 National
BACEless: Eisai, Biogen Pull Plug on Alzheimer’s Drug in Final Stage 09/13/19 Boston
Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs 07/11/19 National
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More 05/03/19 National
Biogen, Taking Its Crisis “Seriously,” Keeps Focus on Neuroscience 04/24/19 Boston
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More 03/29/19 National
Eli Lilly Partners with AC Immune on Tau Blockers for Alzheimer’s 12/12/18 Indiana
Arena’s Comeback Continues with $800M Deal for Lung Disease Drug 11/15/18 San Diego
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More 10/26/18 National
Fresh Data Add More Confusion to Eisai-Biogen Alzheimer’s Drug 10/25/18 Boston
Pernix-Backed Biz Picks Up Orexigen’s Weight Loss Drug for $74M 07/30/18 San Diego
10 Must-Read Stories From Xconomy (and Elsewhere) This Week 07/27/18 National
Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups   07/27/18 National
Eisai & Biogen Reveal Promising Alzheimer’s Data, But Questions Linger 07/26/18 Boston
Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More 07/13/18 National
Biogen, Eisai Claim Success in New Analysis of Failed Alzheimer’s Study 07/06/18 Boston
Bio Roundup: Wrapping ASCO, Dreaming IPO, Rebooting Axovant & More 06/08/18 National
Moving Beyond Obesity, Vivus Strikes $135M Deal for Digestive Drug 05/01/18 San Francisco
Arena Pharma’s Revamp Gains Traction With New Data For GI Drug 03/20/18 San Diego
Bio Roundup: Tax Cuts, Drug Approval Record, New Flagship Cash & More 12/22/17 National
Biogen, Eisai Alzheimer’s Drug Fails First Test But Study Continues 12/21/17 Boston
Startup Builders, IPO Closers & More: Meet Xconomy’s CEO Award Finalists 08/10/17 Boston
Page 1 of 3 next page »